retatrutide triple agonist glp-1 gip glucagon phase 3 2025 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials retatrutide triple agonist glp-1 gip

Newer therapy with potentially greater weight loss in clinical trials

Synthesized in the intestinal L-cells, GLP-1 is secreted in response to food intake, stimulating insulin secretion and inhibiting glucagon release [1]

Mulberry Leaf: Mulberry leaf supports healthy glucose metabolism by slowing carbohydrate absorption and supporting insulin function

Your appetite will stabilize

In clinical trials, Retatrutide treatment normalized liver fat in 90% of patients with NAFLD over 48 weeks, highlighting its significant impact on liver health

If you dropped 2 pounds total in four weeks, that's normal too especially if you started at a lower dose